Background: Distinguishing between sub-clinical and aggressive forms of prostate cancer is difficult due to the heterogeneity of the disease. It is, however, important to identify aggressive forms to guide proper treatment. This study compared gene expression profiles in cancer cells from hereditary and sporadic prostate cancer cases and attempted to correlate differentially regulated genes with clinico-pathological characteristics and prognosis. Materials and Methods: The study population comprised patients diagnosed with clinically localized prostate cancer undergoing prostatectomy. Patients were divided into hereditary and sporadic cancer cases based on their family history. Fresh frozen biopsies from prostatectomy specimens were laser-dissected for RNA-extraction. Affymetrix HG-U133 Plus GeneChips were used to measure gene expression loaded onto Cluster 3.0 and Ingenuity Pathway Analysis softwares to examine the relationship among genes between groups. Differentially expressed genes were selected for protein expression analysis using immunohistochemistry on histological sections and tissue microarrays. Results: No single genes were signifycantly differentially expressed between hereditary and sporadic cases after adjustment for multiple testing. Using cluster analysis, four transcripts were found to be upregulated in hereditary prostate cancer tissue: CYR61, EGR3, KLF6 and SNF1LK. The intensity of CYR61, EGR2, KLF6 and SNF1LK immunostainings, however, were not significantly different in a separate sample of hereditary and sporadic prostate cancers. Furthermore, no correlations between CYR61, EGR2, KLF6, and SNF1LK staining intensities and the clinico-pathological variables or disease-free survival were detected, except for EGR3 that was significantly associated with T stage (p = 0.04). Conclusion: Overall, no single transcript level was significantly associated with hereditary prostate cancer. Cluster analysis suggested that the expression of CYR61, EGR3, KLF6 and SNF1LK were upregulated in cancer tissue from hereditary cases, but we were not able to confirm this on the protein level, and levels of these proteins were not found to correlate with clinico-pathological characteristics or biochemical recurrence.
Introduction
Prostate cancer is the second most common solid cancer worldwide. The role of age, race, ethnicity, and family history of has been described in multiple large epidemicological studies. Familial prostate cancer accounts for 10% -20% of all cases and hereditary prostate cancer (HPC) for 5% -10% [1] [2] [3] . Early age at onset is the only trait convincingly associated with HPC.
The establishment of the Human Genome Project in 1998 and the International HapMap Project has lead to an increased interest in the molecular characterization of prostate cancer [4, 5] . Many studies have addressed the genetic issue in HPC and suggested genes presumably implicated in the cancer disease. HPC1 on chromosome 1q24-25 has been linked to younger cases from families with a strong family history [6, 7] . It has been suggested that RNASEL is linked to HPC1 and involved in prostate cancer susceptibility [8, 9] . Recently, studies on risk loci have converged on chromosome 8q24 within which several polymorphisms with risk alleles reside [10] [11] [12] [13] [14] [15] [16] . Individually, these variants contribute only modestly to risk; combined, they have cumulative risk [17, 18] .
In the current study, we aimed at identifying differentially regulated genes between HPC and SPC tissue and correlate potential expression differences to clinico-pathological characteristics and prognosis.
cases among first-degree relatives in the family, includeing the index person.
Prostate cancer specimens were collected from the Aarhus Prostate Cancer Study biobank. Almost instantly after the prostatectomy, two to four needle biopsies of the tumor were collected macroscopically from the removed prostate. The specimens were snap-frozen in Tissue-Tek in a cryovial by submersion in liquid nitrogen and stored at -80˚C until utilization. The tumors were all primary and classified according to WHO criteria.
The same set of patient samples were not analyzed with each method due to limited availability of tissue samples; however, they all came from the same cohort. The flow chart in Figure 1 shows the inclusion of patients for each analysis.
Microarray Gene Expression Profiling

Laser-Capture Micro-Dissection and
Ribonucleic Acid-Extraction For microdissection, cryosections were prepared from frozen needle biopsies. Each section was cut 5 µm thick and mounted onto an adhesive-coated slide (Brock & Mikkelsen) after they had been left to air-dry on ice for one Flowchart showing which patients were analyzed with microarray, conventional immunohistochemistry, and immunohistochemistry on tissue microarrays, respectively. FH: family history/familial prostate cancer. The fresh frozen tumor tissue of seven patients with HPC and 23 patients with SPC were prepared for microarray expression profile; however, the paraffin-embedded tissue of only some of those patients (4 HPC and 3 SPC cases) was available for immunohistochemical analysis. Tissue from additional patients (4 HPC and 15 SPC cases, randomly selected from the same cohort), was therefore added for conventional immunohistochemistry yielding a total study sample of 8 HPC and 18 SPC cases. There was only a minor overlap between patients included in the tissue microarray and those analayzed for microarray expression profiles and with conventional immunohistochemistry. Blocks of formalin-fixed, paraffin-embedded prostate tustained with hemotoxyr histopathological examination; the secm -20˚C for 2 min and subsequently stained with 1% cresyl violet acetate in room temperature for 20 seconds (s). Following this, the slides were transferred to ethanol (50% and 100%) for 2 × 30 s for dehydration and air-dried at room temperature (20˚C) for approximately 10 min. The cancer lesion was defined and marked prior to microdissection (P.A.L.M Microlaser Technologies, Bernried, Gernmany). Once the selected cancer cells were marked, the energy of the laser light was canalized to catapult the cells into a cap of an Eppendorf microtube. An adequate quantity of captured cells was ensured by dissection of about 10 mm 2 cancer area; the obtained cancer tissue was placed in a microtube with 300 µl lysis buffer and mercapto-ethanol (Pure Gene DNA protocol). RNA was extracted by using a RNA isolation kit (RNeasy Micro Cat. No74004, Qiagen) according to the manufacturer's instructions, except 10 µL DNAase in 70 µL RDD buffer and 500 µL RPE buffer were applied twice and the elution was centrifuged twice. Prior to cDNA amplification, total RNA was quantified and the quality confirmed by RIN scores on a bioanalyzer (Agilent 2100 Bioanalyzer). Five ng total RNAs were required to assure minimum input. The average RIN score was 6.0 ranging from 3.7 to 9.7.
c
Using WT-ovation™ Pico (Pico) (NuGEN Technologies Inc.), the cDNA amplification from total RNA was executed according to Nugen's instruction. DNA/RNA chimeric Primer, Reverse Transcriptase and 5 µl total RNA were mixed with a random primer. Subsequently, 2.5 µl buffer and 0.25 µl enzyme were added to the DNA primer mix. In the next step, 9.75 µl buffer and 0.25 µl enzyme were added to the cDNA solution together with a master mix of SPIA ® buffer (80 µl), primer (40 µl) and enzyme (40 µl 
Hybrid ation
50 µl biotin-labeled c metrix array cartridge hybridizing during 16-hour incubation. Following hybridization, the GeneChip ® probe array was washed and stained (streptavidin-phycoerythrin conjugate 10 mg/ml; Molecular Probes, Eugene, OR) according to the automatic fluidic station protocol. The arrays were scanned and stored until analysis (Hewlett Packard GeneArray Scanner G2500A). A total of 30 Affymetrix GeneChips were used (for detailed description see Thykaer et al.) [19] .
The scanning measures of GeneChip probe arrays were generated and gene expression was normalized using GeneChip robust multi-array analy in ArrayAssist software (Stratagene) [20] . For cluster analysis, two filters were used: 1) gene expression threshold was set at six, probe-sets where less than four samples were measured below six were removed; 2) probesets with variance ≤3 were removed. Cluster 3.0 and Treeview software were used [21] .
The Ingenuity Pathways Knowledge Base contains information about functional annotations and biological interactions between organs, tissues, cells, diseases and drugs. The probe-sets' IDs were uploaded to Ingenuity Pathways Knowledge Base and mapped to its equivalent gene describing part of complex or interactions and networking.
Immunohistochemistry
Tissues
mors were sectioned at 4 µm and lin and eosin fo tions were examined for cancer and diagnosed by a pathologist. Sections of eight HPC and 18 SPC cases were cut for the detection of antigens by immunohistochemistry. Paraffin-embedded prostate cancer tissue from 220 patients were included in a tissue microarray [22, 23] .
For immunohistochemical detection of antigens, sections of formalin-fixed, paraffin-embedded tumors from each patient were stained for the four antigens according to the manufacturer's instructions. Sections were deparaffinized, hydrated to dH 2 O, endogenous peroxidase activty was blocked with H 2 O 2 (3.5 ml 35% H 2 O 2 , Bie & Berntsen), and slides were washed in tris-buffered saline TBS (pH 7.4; Bie & Berntsen). Heat-induced epitope retrieval was performed in a microwave oven in 200 ml Tris-EGTA (TEG buffer; pH 9.0) for 10 minutes at 350 W. Sections were washed in TBS, pre-incubated with 1% bovine serum albumin (BSA; pH 5.2; Applichem A22440100) and diluted for 30 minutes at room temperature. After TBS washing, sections were incubated with primary antibody (Table 1) diluted in 1% BSA for 60 minutes at room temperature. Sections were washed in TBS, covered with horseradish peroxidase-conjugated secondary polyclonal anti-rabbit antibody, visualized and prepared according to Dako's instructions for 30 minutes plus 10 minutes at room temperature (EnVision kit with DAB chromogen, Dako K4003, Glostrup, Denmark). For enhancement of the signal, anti-EGR3 and anti-KLF6 were boosted with signal stain (Cell Signaling) according to the manufacturer's protocol. Sections were rinsed with water, counterstained with hemotoxylin P. Mayer (Sigma), and washed in water. ion, ing results were collected in two categ stain and 1 = stain). Furthermore, the percentage of stained cells was estimated, and it was noted if the staining pattern was focal, diffuse or varying in intensity.
Conventional slides were scored blindly by one researcher, whereas tissue microarray slides were scored blindly by two researchers; in case of interobserver variation, the slides were reevaluated until agreem ached.
Statistical Analysis
Statistics were performed in Excel (Win 07, Microsoft).
To analyz the HPC and SPC groups w performed for each gene an parison with Bonferroni correction. Chi-square tests and Fisher's exact test were used to analyze categorical parameters (staining score, postoperative T stage, postoperative Gleason score, and preoperative PSA) whereas ttest were used to test for differences in age at diagnosis between groups. Time at risk was calculated from the date of surgery to the date of biochemical recurrence or prostate cancer-specific death, and patients without these events were censored at their last blood test. Biochemical recurrence was determined by PSA measurement ≥0.2 ng/ml after radical prostatectomy. Kaplan Meier survival estimates were used to illustrate biochemical relapse over time and the difference in biochemical disease-free sur- 
Results
Three, partly tients with clin family history consistent with either HPC, familial prostate cancer or SPC were analyzed in the present study with microarray gene expression analysis (n = 30), conventional immunohistochemistry (n = 26), or immunohistochemistry on tissue microarray (n = 220) (Figure 1) . Clinical and pathological characteristics of patients analyzed with microarray expression profiles are listed in Table 2 . Patients analyzed with conventional immunohistochemistry are summarized in Table 3 , and cases included in the tissue microarray are listed in Table 4 . The combined group of HPC patients (n = 21) were signifycantly younger than the combined group of SPC cases (n = 195) (mean, 95% CI: 60.9, 59.2 -62.6 versus 63.1, 62.6 -63.6; p = 0.017; F-test was insignificant).
Microarray Data Analysis
A total of 54,676 probesets for studyin scriptome were used for genome-wid seven HPC and 23 SPC cases. Initially, we used t-test statistics to delineate transcripts that were differentially expressed between patients with HPC and SPC. However, following Bonferroni correction none was significant (data not shown). Consequently, we decided to investigate the underlying gene expression patterns using unsupervised hierarchical cluster analysis. Following data reduction, approximately 5500 probesets representing unique transripts remained. The cluster dendrogram and associated heatmap is shown in Figure 2 . 
Characteristics
CYR61 (-) CYR61 (+) EGR3 (-) EGR3 (+) KLF6 (-) KLF6 (+) SNF1LK (-) SNF1LK (+) (n = 107)
(n = 113) (n = 162) (n = 58) (n = 92) (n = 128) (n = 187) (n = 33)
Age at diagnosis-no. (%)
Mean (95% CI) 9) 7) .4) .0) . F1LK he oups was estiOne cluster of tumors included 3 of the 7 HPC cases analyzed. By further investigating an associated gene luster which showed general upregulation of the genes,
Immunohistochemical Analysis
Antibodies against CYR61, EGR3, KLF6 and SN c w were tested on slides from 8 HPC and 18 SPC cases. T fraction of stained tumor cells in both gr e selected a panel of 4 up-regulated transcripts (CYR61, EGR3, KLF6 and SNF1LK), and the corresponding protein products were selected for immunohistochemistry. The general gene expression levels are visualized graphically in Figure 3 : EGR3 (median = 5.47) and SNF1LK (median = 7.75) were observed with an intermediate expression level whereas CYR61 (median = 9.80) had a generally high expression, and KLF6 (median = 5.65) had a generally lower expression level across the samples. Fold changes are summarized in Table 5 . mated ranging from 0% -100% (median, 75%) for CYR1, 80% -100% (90%) for EGR3, 0% -100% (30%) for KLF6, and 0% -100% (0%) for SNF1LK. Cytoplasmic staining of CYR61 and EGR3 and nuclear staining of KLF6 and SNF1LK were expected; however, immunopositivity of every protein was located mainly in the cytoplasma and the membrane and only occasionally observed in cell nuclei. 
Tissue Microarray Analysis
To investigate the potential correlation of CYR61, EGR3, KLF6 and SNF1LK protein levels with clinical characteristics and disease-free survival after prostatectomy, we stained tissue microarrays comprising a larger set of patients with HPC (n = 12) and SPC (n = 152), as well as cancer that did HPC may y a special gene expression profile, and ndidates through microarray gene exof the group of growth factor inenes and a member of the CCN YR61 referral [30] . Cancers in mily. Narla et al inve patients with a family history of prostate not meet the criteria for HPC (n = 56). Staining results were similar to those obtained with conventional histological sections (Figure 4) . The median stained percentage of cells were 10% for CYR61, 50% for KLF6, 5% for EGR3 and SNF1LK. We found no significant differences in staining intensities between HPC and SPC groups. The relationship between clinical characteristics and staining results are summarized in Table 5 . Kaplan Meier curves for biochemical relapse-free survival are shown in Figure 5 . In general, staining intensities of the four proteins did not correlate with the clinico-pathological variables or disease-free survival except for EGR3, which was associated with T stage (p = 0.04).
Discussion
HPC accounts for 5% -10% of all prostate cancer and so far, no clinicopathological phenotypes have been clearly described to distinguish this group from SPC, except early onset [6, [24] [25] [26] [27] [28] [29] . We hypothesized that cases of be characterized b identified four ca pression analysis and unsupervised hierarchical cluster analysis: CYR61, EGR3, KLF6 and SNF1LK. However, we were not able to confirm the differential expression of these genes on the protein level in a separate set of HPC and SPC tumors. Neither were their protein levels correlated with clinical characteristics or biochemical relapse when analyzed in a larger sample of prostate cancer cases, except that EGR3 expression was found to be associated with a low T stage.
Candidate Genes
CYR61 is a member ducible immediate-early g family, hence the CNN/C several organs, including the prostate, have been observed to have an altered expression level of CYR61, which may either stimulate or inhibit tumor growth dependent on the type of cancer [31] [32] [33] [34] [35] [36] . Through its multiple regulatory functions in cardinal cell activities such as apoptosis, proliferation, differentiation, growth arrest and connective tissue production, CYR61 may contribute to angiogenesis, tumorigenesis, wound healing and chondrogenesis. The function and localization of CYR61 are associated with extracellular matrix and cell surfaces. It was originally reported to be down-regulated in prostate cancer; however, we discovered an upregulation of the CYR61 of the transcript in HPC samples. We also observed both a nuclear and cytoplasmic localization of the protein which complies with the findings of Timura et al. in cultured bladder smooth muscle cells [37, 38] . Yet, we assessed no difference in staining intensity between HPC and SPC specimens, and no associations with clinical parameters or biochemical relapse.
KLF6 is a zinc finger transcription factor and a member of Krüppel-like factors equipped with similarly broad biological properties as the CNN fa stigated the expression of a splice form of KLF6 (KLF-SV1) in clinically localized prostate cancer and found that increased expression of KLF6-SV1 predicted biochemical relapse and reduced survival after prostatectomy [39] . In our study, clinico-pathology, heredity and biochemical relapse were not associated with KLF6 expression levels. EGR3 has been identified as a member of the early growth response (EGR) family of transcription factors [40] . We found that the expression level of EGR3 were associated with a lower T stage, but not other clinical parameters or biochemical relapse. Although the association with T stage may be an interesting finding, it cannot be excluded that it may have occured by chance espea tivity of all proteins was detected preferably in the cytoplasma and rather dense luminally, but inconsistently in nuclei.
It was difficult to obtain paraffin blocks for histological validation from the same cases that were analyzed by microarray analysis; as an alternative, we assessed other om the same cohort. The fact that we were not staining intensities and the limited number of samples. However, it may also suggest that the expression differevels were not sufficiently specific or quantitative. On the other hand, mirrored by cially since a significant number of statistical analysis were performed to detect potential associations. SNF1LK erine/threonine-protein kinase (SIK1) is an enzyme. SIK1 able to confirm the gene expression differences on the protein level may be because of the wide variation in S h s been identified as a mediator in metastasis suppression and anoikis [41] . In the present study, however, SNF1LK expression was not associated with heredity, clinical variables or biochemical relapse.
Immunohistochemical Stainings
The staining pattern of our immunohistochemistry was not entirely as expected from previous descriptions. Staining was previously found to be located in nuclei for KLF6 and SNF1LK and be strictly cytoplasmic/membraneous for EGR3 and CYR61 [4] . In our assays, the immunoposiences observed in the microarray gene expression experiment was a chance finding, or that the immunohistological analysis used to analyze protein l cases fr transcriptional differences are not always protein levels. Validation of the gene expression data by quantitative RT-PCR in the same or independent samples would strengten our findings. Moreover, specificity of the immunstaining assays should be further tested, and the findings would also be supported by using an additional method to measure protein levels, e.g. Western blot.
Limitations
Several limitations may have affected our results, including the definition used to identify cases of HPC, the validity of the self-reported family histories, potential genetic heterogeneity of the HPC cases, and the small sample size for microarray gene expression profiling. We based our inclusion to the HPC group on self-reported family history of the patients and Carter's criteria. Although these criteria has been the cornerstone of many major epidemiological studies and biological experiments, it must be kept in mind that the definition by Carter et al. was established on the basis of epidemiological data, and it is not possible to distinguish true cases with HPC from "phenocopies" in the family [42, 43] . Furthermore, even if all HPC cases are correctly classified, they may have different genetic causes.
The discussion about sample size and power in genome-wide studies is complicated by the fact that biological samples are difficult to obtain due to ethical guidelines. The purpose was to characterize the study population in the Aarhus Prostate Cancer Study. Even though we calculated the necessary sample size of HPC cases to 50 in difference in gene expression under order to detect any the null-hypothesis, the sample size for HPC was seven in the microarray study and eight for immunohistochemistry. The microarray technology used requires statistical stringency to consider all genes concurrently and independently [44] . Thus, we used Bonferroni correction to correct for multiple comparisons. However, the power of e microarray study would be increased and the chance for selection of truly differentially expressed genes improved if more cases were included.
Conclusion
Overall, no single transcript levels were significantly associated with HPC in the present study after adjustment for multiple testing. Cluster analysis suggested that the expression of CYR61, EGR3, KLF6 and SNF1LK ere upregulated in cancer tissue from HPC cases, but we were not able to confirm this on the protein level, and protein levels were not found to correlate with clinicopathological characteristics or biochemical recurrence.
